Home›Stock Screener›Kimia Biosciences›Financial Statements

Kimia Biosciences Complete Financial Statements

12 Years of Data
2026 - 2015

In FY2026, Kimia Biosciences (KIMIABL) reported revenue ₹115 Cr, net profit ₹8 Cr and EPS ₹1.64, with a net profit margin of 7.0% and ROE of 44.4%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse KIMIABL promoter holding to track promoter, FII and institutional holdings.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 6.96% 2026 data
EBITDA Margin 12.17% 2026 data
Operating Margin 12.00% 2026 data
Return on Assets 7.77% 2026 data
Return on Equity 44.44% 2026 data

Balance Sheet Ratios

Current Ratio 2.67 2026 data
Equity Ratio 17.48% 2026 data
Asset Turnover 1.12 2026 data

KIMIABL Revenue, Net Profit & EBITDA — Year-on-Year Growth

KIMIABL YoY (March 2025 vs March 2026) — revenue -4.2%, net profit -20.0%, EBITDA -36.4%, expenses +2.0%. Also explore KIMIABL share price charts to track price trends across different timeframes.

Revenue Growth
-4.2%
Year-over-Year
Net Profit Growth
-20.0%
Year-over-Year
EBITDA Growth
-36.4%
Year-over-Year
Expense Growth
+2.0%
Year-over-Year
Assets Growth
-7.2%
Year-over-Year
Equity Growth
+80.0%
Year-over-Year
Operating Cash Flow Growth
+40.0%
Year-over-Year
Investing Cash Flow Growth
-150.0%
Year-over-Year
Financing Cash Flow Growth
-30.8%
Year-over-Year

KIMIABL Income Statement — Revenue, EBITDA & Net Profit

Kimia Biosciences revenue ₹115 Cr, EBITDA ₹14 Cr, net profit ₹8 Cr, EPS ₹1.64 (2026) — net profit margin 7.0%. For live price, earnings ratios and company overview, see KIMIABL share price screener.

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Revenue 115 120 107 130 126 135 107 95 77 2 0 2
Expenses 101 99 105 134 124 124 102 88 74 2 4 4
EBITDA 14 22 1 -4 2 11 5 7 3 0 -3 -1
Operating Profit Margin % 12.00% 17.00% 0.00% -4.00% 1.00% 6.00% 4.00% 6.00% 3.00% -67.00% -1759.00% -110.00%
Depreciation 4 3 3 3 3 2 2 1 1 0 0 0
Interest 4 5 5 4 4 3 3 2 1 0 1 0
Profit Before Tax 8 14 -7 -12 -5 6 1 4 2 -1 -4 -2
Tax 0 4 -2 -3 -1 0 0 0 0 0 0 0
Net Profit 8 10 -5 -9 -4 5 1 4 2 -1 -4 -2
Earnings Per Share (₹) 1.64 2.03 -1.12 -1.98 -0.78 1.08 0.33 2.64 1.14 -1.26 -5.49 -2.31

KIMIABL Balance Sheet — Assets, Liabilities & Shareholders' Equity

KIMIABL total assets ₹103 Cr, total equity ₹18 Cr, total liabilities ₹ Cr (2026) — ROE 44.4%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 103 111 100 121 110 107 86 65 58 12 4 5
Current Assets 64 75 61 83 73 72 61 48 43 2 1 1
Fixed Assets 38 33 32 34 35 28 18 16 13 7 3 3
Capital Work in Progress 0 0 1 1 0 6 6 2 3 3 0 0
Investments 26 0 0 0 0 0 0 0 0 0 0 0
Other Assets 0 78 68 87 74 73 62 48 43 2 1 1
LIABILITIES
Total Liabilities
Current Liabilities 24 19 30 40 33 37 34 29 25 9 7 1
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 18 10 0 6 15 18 13 6 2 -5 -4 0
Share Capital 5 5 5 5 5 5 5 2 2 7 7 7
Reserves & Surplus 13 5 -4 1 10 14 9 2 -2 -12 -11 -7

KIMIABL Cash Flow Statement — Operating, Investing & Financing

Kimia Biosciences operating cash flow ₹21 Cr, investing ₹-5 Cr, financing ₹-17 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 21 15 -7 8 6 0 -3 -7 -1 -6 0
Investing Activities -5 -2 -3 -1 -14 -9 -2 -2 -6 0 0
Financing Activities -17 -13 10 -8 8 9 4 10 7 6 0
Net Cash Flow 0 0 0 0 0 0 -1 1 0 0 0